Jenburkt Pharmaceuticals has received an approval for Buyback of its fully paid-up equity shares of face value of Rs 10 each from its equity shareholders, as on record date to be announced in due course of time, for an amount not exceeding Rs 12 crore, at a price of Rs 576 per equity share which is 22.37% of the fully paid-up equity share capital and free reserves as per the latest audited balance sheet of the company for the financial year ended on March 31, 2017. The Board of Directors of the company at their meeting held on September 09, 2017 has approved for the same.
The Buyback offer will comprise a purchase of up to 2,08,333 equity shares, representing 4.48% of the paid up equity capital of the company. The Buyback offer will be on a proportionate basis through the Tender Offer route as prescribed under the Buyback Regulations, from all of the equity shareholders/ beneficial owners who hold Equity Shares on the record date for the proposed Buyback, which will be determined in due course.
Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1751.05 |
Dr. Reddys Lab | 1163.70 |
Cipla | 1515.45 |
Lupin | 1936.75 |
Zydus Lifesciences | 831.40 |
View more.. |